| name | endo-lipoprotein-a-threshold-cvd-risk-enhancement |
| description | Defines lipoprotein(a) ≥50 mg/dL (125 nmol/L) as a cardiovascular risk-enhancing factor for atherosclerotic cardiovascular disease. Triggered by Lp(a) measurement showing ≥50 mg/dL, assessing Lp(a)'s contribution to CVD risk, or using the Lp(a) threshold for risk stratification. |
Lipoprotein(a) level ≥50 mg/dL as cardiovascular risk-enhancing factor
STEP 1 — Gather Information
Collect personal/family history of premature ASCVD, personal ASCVD, or family history of high Lp(a); obtain Lp(a) level (mg/dL or nmol/L) via immunoassay (fasting or nonfasting acceptable).
STEP 2 — Rule In / Rule Out
If Lp(a) ≥50 mg/dL (≥125 nmol/L), rule in as elevated Lp(a); otherwise rule out.
STEP 3 — Classify or Stratify
If Lp(a) elevated, classify as a risk-enhancing factor; integrate with overall 10-year ASCVD risk (Pooled Cohort Equations) and other risk-enhancing factors.
STEP 4 — Decide
For borderline/intermediate risk (5–19.9% 10-year ASCVD) with elevated Lp(a), consider CAC scoring to guide statin initiation; if high risk (>20%), intensify LDL-C–lowering therapy regardless of CAC.
Clinical Guardrails / Mimics / Pitfalls
Lp(a) testing need not be repeated if previously measured; lowering Lp(a) not proven to reduce ASCVD risk; do not base statin decisions solely on Lp(a); Lp(a) unaffected by fasting status.
Concrete Clinical Example
55‑year‑old man with father’s MI at 58, LDL‑C 130 mg/dL, 10‑year ASCVD risk 12%, Lp(a) 80 mg/dL → elevated Lp(a) → intermediate risk + risk‑enhancing factor → CAC score obtained; CAC=120 → initiate moderate‑intensity statin.
Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674
TODO: consider adding scripts/calc.py for the endo-lipoprotein-a-threshold-cvd-risk-enhancement calculator
